Novavax, Inc. NVAX

NAS: NVAX | ISIN: US6700024010 19/12/2025

6,660 USD (-0,30%)

(-0,30%) 19/12/2025

Grafiek Novavax, Inc.

Grafiek Novavax, Inc.

1 dag1d -0,30%
1 week1w 1,22%
1 maand1m 7,07%
3 maanden3m -24,92%
6 maanden6m 3,90%
1 jaar1j -23,45%
5 jaar5j -94,63%

Novavax, Inc. in het nieuws

Toon enkel gratis nieuws

12 november 2025 · Novavax to Participate in Jefferies London Healthcare Conference · Persbericht

6 november 2025 · Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights · Persbericht

4 november 2025 · Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment · Persbericht

30 oktober 2025 · Novavax to Report Third Quarter 2025 Financial Results on November 6, 2025 · Persbericht

22 oktober 2025 · Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy · Persbericht

7 oktober 2025 · Novavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment · Persbericht

30 september 2025 · Novavax Announces Progress on Sanofi Agreement · Persbericht

4 september 2025 · Nuvaxovid® Now Approved in Japan Triggering Takeda Milestone Payment · Persbericht

3 september 2025 · Novavax to Participate in the Cantor Global Healthcare Conference · Persbericht

27 augustus 2025 · Novavax's Nuvaxovid™ 2025-2026 Formula COVID-19 Vaccine Approved in the U.S. · Persbericht

Profiel Novavax, Inc.

Gezondheidstechnologie

Productie van biologische producten

Website: www.novavax.com

Hoofdzetel: Gaithersburg, Maryland Verenigde Staten

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe